Clínica Baviera Valuation
Is D9Z undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of D9Z when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: D9Z (€33.8) is trading below our estimate of fair value (€58.97)
Significantly Below Fair Value: D9Z is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for D9Z?
Key metric: As D9Z is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is D9Z's PE Ratio? | |
|---|---|
| PE Ratio | 14.4x |
| Earnings | €37.07m |
| Market Cap | €533.95m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does D9Z's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 16.6x | ||
RHK RHÖN-KLINIKUM | 18.9x | 7.5% | €850.1m |
M12 M1 Kliniken | 17.5x | 17.5% | €293.2m |
LIK LIMES Schlosskliniken | 23.2x | n/a | €99.1m |
JTH Gesundheitswelt Chiemgau | 6.8x | n/a | €23.8m |
D9Z Clínica Baviera | 14.4x | n/a | €534.0m |
Price-To-Earnings vs Peers: D9Z is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (16.6x).
Price to Earnings Ratio vs Industry
How does D9Z's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: D9Z is good value based on its Price-To-Earnings Ratio (14.4x) compared to the European Healthcare industry average (18.8x).
Price to Earnings Ratio vs Fair Ratio
What is D9Z's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate D9Z's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.6b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
1.0%
1Y
-34.2%
LNA Santé
€234.2m
Engages in the management and operation of health establishments.
2N3
€22.30
7D
-4.9%
1Y
16.8%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%